Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra

Human Gene Therapy
Ronald L KleinEdwin M Meyer

Abstract

Somatic cell gene transfer was used to express a mutant form of alpha-synuclein (alpha-syn) that is associated with Parkinson's disease (PD) in the rat substantia nigra (SN), a brain region that, in humans, degenerates during PD. DNA encoding the A30P mutant of human alpha-syn linked to familial PD was incorporated into an adeno-associated virus vector, which was injected into the adult rat midbrain. The cytomegalovirus/chicken beta-actin promoter was used to drive transgene expression. Over a 1-year time course, this treatment produced three significant features relevant to PD: (1) accumulation of alpha-syn in SN neuron perikarya, (2) Lewy-like dystrophic neurites in the SN and the striatum, and (3) a 53% loss of SN dopamine neurons. However, motor dysfunction was not found in either rotational or rotating rod testing. The lack of behavioral deficits, despite the significant cell loss, may reflect pathogenesis similar to that of PD, where greater than 50% losses occur before motor behavior is affected.

References

Jun 13, 1998·Human Gene Therapy·J S BartlettT J McCown
Apr 29, 1999·Brain : a Journal of Neurology·P Shammi, D T Stuss
Oct 12, 1999·Brain Pathology·D W Dickson
Oct 12, 1999·Brain Pathology·J Q Trojanowski, V M Lee
Feb 26, 2000·Proceedings of the National Academy of Sciences of the United States of America·B L DavidsonJ A Chiorini
Apr 4, 2000·Nature·C Haass, P J Kahle
Apr 4, 2000·Nature·M B Feany, W W Bender
Jul 6, 2000·Journal of Neuroscience Methods·A L Peel, R L Klein

❮ Previous
Next ❯

Citations

Apr 1, 2003·Annals of Neurology·Kevin St P McNaught, C Warren Olanow
Apr 28, 2006·Experimental Brain Research·Heather L MelroseMatthew J Farrer
Dec 15, 2011·Acta Neuropathologica·Grit TaschenbergerSebastian Kügler
Mar 12, 2010·Apoptosis : an International Journal on Programmed Cell Death·Toru Yasuda, Hideki Mochizuki
Sep 1, 2012·Molecular Neurobiology·Toru YasudaHideki Mochizuki
Jun 25, 2009·Neurotoxicity Research·Leslie CrewsEliezer Masliah
Aug 12, 2009·Neurotoxicity Research·Ronald L KleinMichael A King
May 8, 2013·Trends in Molecular Medicine·Angélique DeleersnijderVeerle Baekelandt
Mar 18, 2004·Neuroscience Letters·Christophe WersingerAnita Sidhu
Dec 6, 2005·Molecular Therapy : the Journal of the American Society of Gene Therapy·Ronald L KleinRichard M Zweig
Jun 20, 2003·Neuropharmacology·Kumlesh K DevHerman van der Putten
Jul 10, 2003·Trends in Neurosciences·Deniz Kirik, Anders Björklund
Sep 24, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Hemraj B DodiyaJeffrey H Kordower
Feb 19, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Jason B TatomRonald L Klein
Feb 9, 2012·Proceedings of the National Academy of Sciences of the United States of America·Martin LundbladAnders Björklund
Mar 21, 2008·Molecular & Cellular Proteomics : MCP·Zhiyin XunDavid E Clemmer
Mar 11, 2009·Antioxidants & Redox Signaling·Saurabh Sen, Andrew B West
Mar 12, 2005·Human Gene Therapy·Masanori YamadaHideki Mochizuki
Feb 17, 2007·Brain : a Journal of Neurology·Andisheh EslamboliDeniz Kirik
Jun 30, 2011·Brain : a Journal of Neurology·Mickael DecressacAnders Björklund
Aug 16, 2008·The Journal of Clinical Investigation·Christophe Lo BiancoPatrick Aebischer
Nov 21, 2013·Acta Neuropathologica Communications·Hemi DimantPamela J McLean
Oct 4, 2011·PloS One·Claus RiekerDerya R Shimshek
Jul 25, 2008·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Hui-Ming GaoVirginia M-Y Lee
Jan 15, 2011·Parkinson's Disease·Shin Hisahara, Shun Shimohama
Feb 14, 2009·International Journal of Biological Sciences·Hongxia ZhouXu Gang Xia
Jun 13, 2013·Brain : a Journal of Neurology·Maria XilouriLeonidas Stefanis
Oct 23, 2002·Proceedings of the National Academy of Sciences of the United States of America·Kathy Steece-CollierJeffrey H Kordower
Dec 4, 2004·Proceedings of the National Academy of Sciences of the United States of America·Christophe Lo BiancoPatrick Aebischer
Oct 27, 2004·Cell and Tissue Research·Oliver von Bohlen Und Halbach
Nov 3, 2010·Annual Review of Pathology·Joshua M ShulmanMel B Feany
Jul 3, 2003·Médecine sciences : M/S·Olga Corti, Alexis Brice
Feb 10, 2016·Frontiers in Neuroscience·Timothy J CollierFredric P Manfredsson
Feb 3, 2016·Frontiers in Neuroscience·Marion DelenclosPamela J McLean
Feb 3, 2016·Frontiers in Neuroscience·Shail A JagmagSukant Khurana
Mar 4, 2008·Neurobiology of Disease·Alessandra RecchiaPietro Giusti

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell-Type-Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Amygdala and Midbrain Dopamine

The midbrain dopamine system is widely studied for its involvement in emotional and motivational behavior. Some of these neurons receive information from the amygdala and project throughout the cortex. When the circuit and transmission of dopamine is disrupted symptoms may present. Here is the latest research on the amygdala and midbrain dopamine.

Cell-Type Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cell-Type-Specific Viral Vectors (ASM)

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Alpha-Synuclein Aggregation (MDS)

Alpha-synucleins are small proteins that are believed to restrict the mobility of synpatic vesicles and inhibit neurotransmitter release. Aggregation of these proteins have been linked to several types of neurodegenerative diseases including dementia with Lewy bodies and Parkinson's disease. Here is the latest research on α-synuclein aggregation.